Actively Recruiting

Phase Not Applicable
Age: 6Years - 14Years
All Genders
NCT06599879

Irradiation in Paediatrics: Neurocognition, Neuroimaging and Evaluation of Memory and Attention

Led by Institut Claudius Regaud · Updated on 2026-04-13

130

Participants Needed

15

Research Sites

258 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a prospective, open-label, multicentric study designed to correlate the dose delivered to the hippocampus with declarative memory deficits 2 years after radiotherapy treatment in a paediatric population who had received brain irradiation between the ages of 4 and 12 for a brain tumour. In order to meet this objective, several neuropsychological assessments consisting of parental questionnaires and cognitive tests will be carried out during the course of the study, at the following two stages: * A 1st assessment at patient inclusion, i.e. 2 years after the end of radiotherapy treatment, * And a second assessment 2 years after patient inclusion, i.e. 4 years after the end of radiotherapy treatment. A retrospective assessment of the patient's neurocognitive level 1 year before the diagnosis of the disease will also be carried out at inclusion, with the parents completing a questionnaire specifically designed for the trial. In addition, patients who have received their radiotherapy treatment at the IUCT-O will be offered participation in the ancillary imaging study. If the parents and the patient agree, multimodal MRI scans specific to the study (without injection of contrast) will be performed at inclusion and 2 years after inclusion. Imaging and radiotherapy data will be collected in parallel using the PediaRT software used in current practice (collection of radiotherapy dosimetric data as well as standard MRI examinations pre-operatively, post-operatively, and at the 2-year and 4-year follow-up). 130 patients will be included in this study.

CONDITIONS

Official Title

Irradiation in Paediatrics: Neurocognition, Neuroimaging and Evaluation of Memory and Attention

Who Can Participate

Age: 6Years - 14Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patient who has received localised brain irradiation or craniospinal irradiation for a brain tumour whose treatment includes first-line radiotherapy.
  • Patient with one of the following tumour types: ependymomas, medulloblastomas, malignant germ cell tumours, craniopharyngioma, pinealoblastoma.
  • Patient aged between 4 and 12 years at the time of radiotherapy treatment.
  • End of irradiation within 2 years (+/-3 months) prior to inclusion.
  • Patient having been treated by photontherapy or proton therapy.
  • Sufficient visual, auditory (with authorised hearing aid) and oral or written expression capacity to carry out the neuropsychological tests properly.
  • Proficiency in the French language by the patient and parent(s).
  • Patient affiliated to a Social Security scheme in France.
  • Informed consent signed by the patient/legal parent(s)/guardian(s) in accordance with French law and Good Clinical Practice.
Not Eligible

You will not qualify if you...

  • Patient presenting with severe ataxia.
  • Patient with a recurrence of the disease.
  • Not applicable since protocol version 2. Metastatic patient.
  • Any contraindication to MRI for patients included in Toulouse (i.e. in particular patients with a pacemaker or cardiac defibrillator, implanted equipment activated by an electrical, magnetic or mechanical system, patients with haemostatic clips on intracerebral aneurysms, patients with orthopaedic implants, claustrophobic patients).
  • Patients undergoing psychostimulant or psychotropic treatment (in particular methylphenidate, antidepressants).
  • Any psychological, family, geographical or sociological condition that prevents compliance with medical monitoring and/or the procedures set out in the study protocol.
  • Patients deprived of their liberty or under legal protection.
  • Severe posterior fossa syndrome with akinetic mutism.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 15 locations

1

CHU Angers

Angers, France

Actively Recruiting

2

CHU de Bordeaux

Bordeaux, France

Actively Recruiting

3

Centre François Baclesse

Caen, France

Actively Recruiting

4

Centre Georges François Leclerc

Dijon, France

Not Yet Recruiting

5

Centre Oscar Lambret

Lille, France

Not Yet Recruiting

6

Centre Léon Bérard

Lyon, France

Actively Recruiting

7

APHM - Hôpital la Timone

Marseille, France

Not Yet Recruiting

8

Institut du Cancer de Montpellier

Montpellier, France

Not Yet Recruiting

9

Institut Curie

Paris, France

Not Yet Recruiting

10

Centre Eugène Marquis

Rennes, France

Not Yet Recruiting

11

Institut de Cancérologie de l'Ouest

Saint-Herblain, France

Not Yet Recruiting

12

Centre Paul Strauss

Strasbourg, France

Actively Recruiting

13

IUCT-O

Toulouse, France

Actively Recruiting

14

Institut de Cancérologie de Lorraine

Vandœuvre-lès-Nancy, France

Actively Recruiting

15

Institut Gustave Roussy

Villejuif, France

Actively Recruiting

Loading map...

Research Team

A

Anne LAPRIE

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

OTHER

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here